A5036986840- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- Cytomegalovirus and herpesvirus research
- vaccines and immunoinformatics approaches
- HIV, TB, and STIs Epidemiology
- Herpesvirus Infections and Treatments
- Sex work and related issues
- Microfinance and Financial Inclusion
- Genital Health and Disease
- Virology and Viral Diseases
- interferon and immune responses
- HIV/AIDS Impact and Responses
- Hepatitis B Virus Studies
- Poverty, Education, and Child Welfare
- HIV-related health complications and treatments
University of Botswana
2018-2024
Botswana Harvard AIDS Institute Partnership
2013-2019
The development of biomedical interventions to reduce acquisition HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high envelope diversity. Two large prophylactic trials in incidence, clade C epidemic regions southern Africa are imminent; passive administration the monoclonal antibody VRC01, and active immunization with modified RV144-like vaccines. We have created representative panel viruses enable assessment responses vaccines natural...
There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings southern Africa where HIV-1 subtype C predominates. We report a patient infected with DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations four classes. is need for drug monitoring and clinical vigilance ensure HIV treatment programs even era ART.
Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. There is a cross-resistance mutation profile between first- NNRTI drugs. We determined the prevalence of HIV-1 drug resistance mutations (DRMs) to RPV ETR in Botswana. A total 168 polymerase gene sequences from participants failing nevirapine (NVP)- or efavirenz (EFV)-containing regimens were analyzed DRMs using Stanford University database....
Background Roll-out of Integrase Strand Transfer Inhibitors (INSTIs) such as dolutegravir for HIV combination antiretroviral therapy (cART) in sub-Saharan Africa necessitates the development affordable drug resistance (HIVDR) assays targeting gene. We optimised and evaluated an in-house integrase HIV-1 assay (IH-Int) compared it to a commercially available assay, ViroSeq™ Genotyping kit (VS-Int) amongst clade C infected individuals. Methods used 54 plasma samples from treatment naïve...
HIV-1 uses the coreceptors CCR5 and/or CXCR4 for cell entry. Monotropic CCR5-using variants are found early in infection while CXCR4-using may appear after progression to AIDS. use consist of both monotropic and dualtropic viruses. The viral phenotype is important evaluating response inhibitors, a new class antiviral drugs. coreceptor was investigated using population sequencing 24 patients from Botswana, carrying subtype C failing antiretroviral treatment, 26 treatment-naive acted as...
ObjectiveWe utilize a large retrospective study cohort derived from electronic medical records (EMR) to estimate the prevalence of long-term non-progression (LTNP) and determine factors associated with progression among children infected HIV in Botswana Uganda.MethodsEMRs tertiary clinical centers Uganda were queried identify LTNP 0–18 years enrolled between June 2003 May 2014 extract demographic nutritional parameters. Multivariate subdistribution hazard analyses used examine status pre-ART...
Killer-cell immunoglobulin-like receptors (
Background: Despite antiretroviral therapy (ART) and prevention of mother-to-child transmission programs, more than 150,000 new HIV infections 99,000 deaths occur annually among children in Africa. Some - long-term nonprogressors (LTNP) can survive for ten years without progressing from infection to AIDS maintain normal CD4+ T-cell counts the absence ART. However, frequency demography pediatric LTNP Africans remains unknown. Here, we utilize a large retrospective study cohort derived...